Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Pegadricase

            Therapeutic Area: Musculoskeletal Product Name: SEL-212

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Selecta Biosciences

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            Details:

            The phase 3 DISSOLVE clinical programme a randomized double-blind, placebo-controlled study in which SEL-212 will be evaluated at two doses of ImmTOR, and one dose of pegadricase in both studies.